National Cancer Institute NIHBETHESDA, MARYLAND, United States
Disclosures:
2600 - Evaluating Serum CXCL Levels as Potential Biomarkers in Glioblastoma: Observed Alteration with Concurrent Chemoirradiation in Upfront Management
Monday, September 30, 202410:45 AM – 12:00 PM ET